Mosadeghi Parvin, Zarnagh Hafez Heydari, Mohammad-Zadeh Mohammad, Salehi Moghaddam Masoud
Department of Biology, Basic Science Faculty, Payam Noor University of Mashhad, Mashhad, Iran.
Molecular and Cellular research Center, Sabzevar University of Medical Science, Sabzevar, Iran.
Iran J Allergy Asthma Immunol. 2015 Dec;14(6):624-32.
Expression of HTLV-I p19 protein in an Escherichia coli expression system always leads to the formation of inclusion body. Solubilisation and refolding of the inclusion bodies is complex, time consuming and difficult during large-scale preparation. This study aimed to express and purify a soluble form of recombinant HTLV-I p19 protein in an E. coli expression system. The synthetic DNA encoding the p19 was subcloned into a pGS21a vector along with a His-GST solubility/purification tag. The recombinant pGS21a-p19 vector was then transformed into chemically competent E. coli BL21 (DE3) cells, and expression of the recombinant His-GST-p19 protein was induced by IPTG. Expression and distribution of the His-GST-p19 protein in soluble and insoluble fractions were evaluated using SDS-PAGE. Antigenicity of the His-GST-p19 protein was evaluated using ELISA after purifying the protein using Ni-NTA affinity chromatography, then compared to the results of synthetic immunodominant p19 peptide ELISA. The fusion His-GST-p19 protein accounted for 30% of the total cellular proteins. The SDS-PAGE results indicated that approximately 50% of the expressed His-GST-p19 proteins were soluble and accounted for 50% of the total soluble proteins. ELISA showed that the His-GST tag did not impair the antigenicity of the p19 protein and that the fusion protein reacted with HTLV-I antibodies in a concentration-dependent manner. The results of His-GST-p19 ELISA indicated that specificity of p19 reactivity was compatible to the results of p19 peptide ELISA. Combination of key strategies for the soluble expresion of proteins, like fusion with solubility/purification tags, low IPTG concentration and induction at low temperature, provide an efficient and facile platform for producing soluble HTLV-I p19 protein.
人类嗜T淋巴细胞病毒I型(HTLV-I)p19蛋白在大肠杆菌表达系统中的表达总是导致包涵体的形成。在大规模制备过程中,包涵体的溶解和重折叠复杂、耗时且困难。本研究旨在在大肠杆菌表达系统中表达并纯化可溶性形式的重组HTLV-I p19蛋白。将编码p19的合成DNA与His-GST溶解性/纯化标签一起亚克隆到pGS21a载体中。然后将重组pGS21a-p19载体转化到化学感受态大肠杆菌BL21(DE3)细胞中,并用异丙基-β-D-硫代半乳糖苷(IPTG)诱导重组His-GST-p19蛋白的表达。使用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)评估His-GST-p19蛋白在可溶性和不溶性组分中的表达及分布。在使用镍-次氮基三乙酸(Ni-NTA)亲和层析纯化蛋白后,使用酶联免疫吸附测定(ELISA)评估His-GST-p19蛋白的抗原性,然后与合成免疫显性p19肽ELISA的结果进行比较。融合His-GST-p19蛋白占总细胞蛋白的30%。SDS-PAGE结果表明,大约50%的表达的His-GST-p19蛋白是可溶的,占总可溶性蛋白的50%。ELISA表明,His-GST标签不损害p19蛋白的抗原性,并且融合蛋白与HTLV-I抗体以浓度依赖的方式反应。His-GST-p19 ELISA的结果表明,p19反应性的特异性与p19肽ELISA的结果一致。蛋白质可溶性表达的关键策略的组合,如与溶解性/纯化标签融合、低IPTG浓度和低温诱导,为生产可溶性HTLV-I p19蛋白提供了一个高效且简便的平台。